
China’s fast-track trials open to companies as child deaths spotlight risks
The story in brief
China’s fast-track clinical trials for new biomedical technologies are now open to companies, changing rules that previously required trials at Sanjia hospitals. The deaths of children have drawn attention to the risks, while a grey market has emerged with unauthorized therapies. Stricter rules were introduced months before the incidents, but the trials remain ongoing.